Sunshine Biopharma Inc. (SBFM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SBFM SEC filings page.
Sunshine Biopharma Inc. (SBFM) reported $35.3M in revenue over the twelve months to Jun 30, 2026, down 2.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is growing, but overhead still absorbs gross profit; 2025 cash pressure eased mainly as capital spending fell.
Operating cash outflow fell from$12.5M in FY2024 to$5.3M in FY2025 as capex fell to$174K ; because the company still posted a net loss of$6.0M , the cash improvement reflects lighter reinvestment as well as lower operating drain, not profitability.
Gross margin recovered to
The balance sheet is lightly leveraged at 0.3x debt-to-equity and has a 4.2x current ratio, so near-term obligations are not the main constraint. Inventory rose to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sunshine Biopharma Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sunshine Biopharma Inc. held $9.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $5.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Sunshine Biopharma Inc. scores 46/100 among other emerging companies.
Sunshine Biopharma Inc. had 5M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Sunshine Biopharma Inc. scores 97/100 among other emerging companies.
Sunshine Biopharma Inc. spent $604K on research and development in fiscal year 2025, which was 1.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Sunshine Biopharma Inc. scores 11/100 among other emerging companies.
Sunshine Biopharma Inc. reported revenue of $36.3M in fiscal year 2025, against $34.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Sunshine Biopharma Inc. scores 66/100 among other emerging companies.
Sunshine Biopharma Inc.'s operations used $5.3M of cash in fiscal year 2025, against $12.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Sunshine Biopharma Inc. scores 66/100 among other emerging companies.
Sunshine Biopharma Inc.'s cash, cash equivalents and investments came to $9.1M at the end of fiscal year 2025, against $7.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Sunshine Biopharma Inc. scores 65/100 among other emerging companies.
Sunshine Biopharma Inc. scores -1.92, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.7M) relative to total liabilities ($7.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sunshine Biopharma Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Sunshine Biopharma Inc. reported a net loss of $6.0M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Sunshine Biopharma Inc. generated $9.3M in revenue in Q2 2026. This represents a decrease of 1.6% from the same quarter a year earlier. Against the prior quarter it is up 14.5%.
Sunshine Biopharma Inc.'s EBITDA was -$1.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.6% from the same quarter a year earlier. Against the prior quarter it is down 16.4%.
Sunshine Biopharma Inc. reported -$1.6M in net income in Q2 2026. This represents an increase of 11.7% from the same quarter a year earlier. Against the prior quarter it is down 25.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
Sunshine Biopharma Inc. recorded an outflow of $925K in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 35.5% from the same quarter a year earlier. Against the prior quarter it is up 55.5%.
Sunshine Biopharma Inc. held $13.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Sunshine Biopharma Inc.'s gross margin was 26.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 10.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
Sunshine Biopharma Inc.'s operating margin was -17.4% in Q2 2026, reflecting core business profitability. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.
Sunshine Biopharma Inc.'s net profit margin was -16.9% in Q2 2026, showing the share of revenue converted to profit. This is up 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.5 percentage points.
Sunshine Biopharma Inc.'s ROE was -5.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Capital Allocation
Sunshine Biopharma Inc. invested $13K in research and development in Q2 2026. This represents a decrease of 93.3% from the same quarter a year earlier. Against the prior quarter it is down 58.3%.
Sunshine Biopharma Inc. invested $7K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 95.6% from the same quarter a year earlier. Against the prior quarter it is up 36.8%.
Not reported for Q2 2026.
SBFM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M-1.6% | $8.1M-9.1% | $8.6M-10.6% | $9.4M+11.6% | $9.4M+1.2% | $8.9M+18.0% | $9.6M+24.9% | $8.4M+41.6% |
| Cost of Revenue | $6.8M+14.2% | $5.9M-4.3% | $5.5M-14.7% | $6.3M+13.9% | $6.0M-13.8% | $6.2M+19.0% | $6.5M+27.2% | $5.6M+40.4% |
| Gross Profit | $2.4M-29.1% | $2.2M-20.1% | $3.0M-2.1% | $3.1M+7.2% | $3.4M+45.3% | $2.7M+16.0% | $3.1M+20.4% | $2.9M+44.0% |
| R&D Expenses | $13K-93.3% | $32K-85.3% | $74K-50.8% | $119K-5.6% | $196K-55.0% | $215K-3.0% | $149K-81.7% | $126K-46.9% |
| SG&A Expenses | $4.0M-26.3% | $3.6M-11.2% | $4.8M-7.0% | $4.2M+4.7% | $5.5M+51.1% | $4.0M+8.7% | $5.2M+38.8% | $4.0M+43.4% |
| Operating Income | -$1.6M+21.5% | -$1.4M-7.7% | -$1.8M+14.2% | -$1.1M+1.8% | -$2.1M-62.0% | -$1.3M+4.1% | -$2.1M-79.4% | -$1.1M-41.9% |
| EBITDA | -$1.5M+22.6% | -$1.3M-7.1% | -$1.7M+16.3% | -$991K+4.9% | -$2.0M-62.8% | -$1.2M+5.9% | -$2.0M-77.4% | -$1.0M-42.4% |
| Interest Expense | N/A | N/A | $0+100.0% | $0 | $0-100.0% | $0-100.0% | -$41K-235.0% | $0-100.0% |
| Income Tax | $0+100.0% | $0+100.0% | $408K+417.2% | -$137K-163.9% | -$209K+39.1% | -$40K-279.7% | -$129K-158.4% | $215K+425.5% |
| Net Income | -$1.6M+11.7% | -$1.2M-5.4% | -$2.1M+0.8% | -$884K+26.2% | -$1.8M-258.3% | -$1.2M+8.1% | -$2.2M-72.7% | -$1.2M-83.9% |
| EPS (Basic) | -$1.15+70.8% | -$0.25+43.2% | -$0.46-107.3% | -$0.19+79.8% | -$3.94+60.4% | -$0.44+78.0% | $6.29+2047.4% | -$0.94-1754.0% |
| EPS (Diluted) | N/A | N/A | N/A | N/A | -$0.82 | -$0.44 | $6.29 | N/A |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | 4M | 3M | N/A | 1M |
SBFM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $33.6M+5.2% | $27.9M-4.3% | $30.1M-1.6% | $31.5M+4.8% | $32.0M+9.1% | $29.2M-8.5% | $30.6M+11.8% | $30.1M+8.7% |
| Current Assets | $30.7M+10.1% | $24.8M+1.2% | $26.9M+3.4% | $28.0M+7.6% | $27.9M+8.2% | $24.5M-15.1% | $26.0M+4.3% | $26.0M+2.2% |
| Cash & Equivalents | $13.7M+33.4% | $6.9M-14.9% | $9.1M-5.8% | $9.3M-23.8% | $10.3M-10.4% | $8.1M-53.4% | $9.7M-40.5% | $12.2M-35.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $12.1M-6.9% | $13.2M+11.1% | $13.5M+19.5% | $14.1M+43.2% | $13.0M+53.3% | $11.9M+54.0% | $11.3M+96.7% | $9.8M+117.4% |
| Accounts Receivable | $4.0M+12.5% | $4.0M+16.4% | $3.5M-10.6% | $4.2M+29.1% | $3.6M-9.7% | $3.4M+21.8% | $3.9M+51.6% | $3.2M+58.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Total Liabilities | $6.1M-3.0% | $6.4M-1.1% | $7.0M-0.3% | $7.3M+45.3% | $6.3M+8.1% | $6.5M-8.4% | $7.1M+15.0% | $5.0M-11.8% |
| Current Liabilities | $5.6M+0.8% | $5.9M+2.0% | $6.4M+2.0% | $6.7M+46.9% | $5.6M+5.2% | $5.8M-11.8% | $6.3M+13.7% | $4.5M-11.0% |
| Non-Current Liabilities | $476K-32.7% | $536K-25.8% | $597K-19.9% | $637K+30.2% | $707K+38.1% | $722K+32.3% | $745K+26.7% | $489K-18.3% |
| Total Equity | $27.5M+7.2% | $21.5M-5.2% | $23.0M-2.0% | $24.2M-3.4% | $25.7M+9.3% | $22.7M-8.5% | $23.5M+10.8% | $25.0M+14.0% |
| Retained Earnings | -$77.8M-8.1% | -$76.3M-8.6% | -$75.0M-8.7% | -$72.9M-9.0% | -$72.0M-9.6% | -$70.2M-7.7% | -$69.0M-8.0% | -$66.9M-6.7% |
Not reported in any period shown, so not listed: Long-Term Debt.
SBFM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$918K+27.9% | -$2.1M-22.2% | -$1.6M+52.5% | -$747K+45.0% | -$1.3M+72.2% | -$1.7M+46.8% | -$3.4M-26.6% | -$1.4M-196.7% |
| Depreciation & Amortization | $78K+7.5% | $77K+18.6% | $99K+50.7% | $96K+48.3% | $73K+42.6% | $65K+52.0% | $65K+178.8% | $65K+34.6% |
| Capital Expenditures | $7K-95.6% | $5K-31.5% | -$1K-99.0% | $8K-98.4% | $160K-83.6% | $7K-88.1% | $103K-73.2% | $517K+5266.5% |
| Free Cash Flow | -$925K+35.5% | -$2.1M-22.0% | -$1.6M+53.9% | -$755K+59.7% | -$1.4M+74.2% | -$1.7M+47.6% | -$3.5M-14.2% | -$1.9M-301.3% |
| Investing Cash Flow | -$5K+99.1% | -$105K+50.7% | -$50K+48.6% | -$24K+96.4% | -$550K-1.5% | -$212K+68.3% | -$98K+63.7% | -$671K-3655.9% |
| Financing Cash Flow | $7.8M+112.7% | $0-100.0% | $725K-55.2% | $0-100.0% | $3.7M+12934.9% | $355K-93.4% | $1.6M+5402.3% | $2.0M+3173.7% |
| Dividends Paid | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 |
| Share Buybacks | N/A | N/A | $0 | $0 | $0 | $0-100.0% | $0 | $0 |
Not reported in any period shown, so not listed: Stock-Based Compensation.
SBFM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 26.2%-10.2pp | 27.0%-3.7pp | 35.3%+3.1pp | 32.6%-1.3pp | 36.4%+11.0pp | 30.7%-0.6pp | 32.2%-1.2pp | 34.0%+0.6pp |
| Operating Margin | -17.4%+4.4pp | -17.3%-2.7pp | -20.9%+0.9pp | -11.5%+1.6pp | -21.8%-8.2pp | -14.6%+3.4pp | -21.8%-6.6pp | -13.1%0.0pp |
| Net Margin | -16.9%+1.9pp | -15.4%-2.1pp | -25.0%-2.5pp | -9.4%+4.8pp | -18.8%-13.5pp | -13.3%+3.8pp | -22.5%-6.2pp | -14.2%-3.3pp |
| Return on Equity | -5.7%+1.2pp | -5.8%-0.6pp | -9.3%-0.1pp | -3.6%+1.1pp | -6.9%-4.8pp | -5.2%0.0pp | -9.2%-3.3pp | -4.8%-1.8pp |
| Return on Assets | -4.7%+0.9pp | -4.5%-0.4pp | -7.1%-0.1pp | -2.8%+1.2pp | -5.5%-3.9pp | -4.0%0.0pp | -7.1%-2.5pp | -4.0%-1.6pp |
| Current Ratio | 5.46+0.5x | 4.220.0x | 4.17+0.1x | 4.20-1.5x | 5.00+0.1x | 4.25-0.2x | 4.11-0.4x | 5.74+0.7x |
| Debt-to-Equity | 0.220.0x | 0.300.0x | 0.310.0x | 0.30+0.1x | 0.240.0x | 0.290.0x | 0.300.0x | 0.20-0.1x |
| Asset Turnover | 0.280.0x | 0.290.0x | 0.290.0x | 0.300.0x | 0.290.0x | 0.30+0.1x | 0.310.0x | 0.28+0.1x |
| FCF Margin | -10.0%+5.2pp | -25.7%-6.5pp | -18.9%+17.7pp | -8.0%+14.2pp | -15.2%+44.5pp | -19.1%+23.9pp | -36.6%+3.4pp | -22.2%-14.4pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Sunshine Biopharma Inc. SBFM | FY2025 | $36.3M | -$6.0M | -16.5% | $2.7M | 59/100 |
| Sonoma Pharmaceuticals, Inc. SNOA | FY2026 | $19.5M | $3K | 0.0% | $5.9M | 40/100 |
| cbdMD, Inc. YCBD | FY2025 | $19.2M | -$2.0M | -10.6% | $4.6M | 38/100 |
| Biofrontera Inc. BFRI | FY2025 | $41.7M | -$10.5M | -25.3% | $13.8M | 39/100 |
| Evoke Pharma, Inc. EVOK | FY2024 | $10.2M | -$5.4M | -52.2% | $18.9M | 58/100 |
| China Pharma Holdings, Inc. CPHI | FY2025 | $4.1M | -$3.2M | -76.9% | $27.6M | 40/100 |
Where Sunshine Biopharma Inc. Ranks
Frequently Asked Questions
What is Sunshine Biopharma Inc.'s annual revenue?
Sunshine Biopharma Inc. (SBFM) reported $36.3M in total revenue for fiscal year 2025. This represents a 4.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sunshine Biopharma Inc.'s revenue growing?
Sunshine Biopharma Inc. (SBFM) revenue grew by 4.1% year-over-year, from $34.9M to $36.3M in fiscal year 2025.
Is Sunshine Biopharma Inc. profitable?
No, Sunshine Biopharma Inc. (SBFM) reported a net income of -$6.0M in fiscal year 2025, with a net profit margin of -16.5%.
What is Sunshine Biopharma Inc.'s EBITDA?
Sunshine Biopharma Inc. (SBFM) had EBITDA of -$5.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sunshine Biopharma Inc.'s gross margin?
Sunshine Biopharma Inc. (SBFM) had a gross margin of 33.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sunshine Biopharma Inc.'s operating margin?
Sunshine Biopharma Inc. (SBFM) had an operating margin of -17.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sunshine Biopharma Inc.'s net profit margin?
Sunshine Biopharma Inc. (SBFM) had a net profit margin of -16.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sunshine Biopharma Inc.'s return on equity (ROE)?
Sunshine Biopharma Inc. (SBFM) has a return on equity of -25.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sunshine Biopharma Inc.'s free cash flow?
Sunshine Biopharma Inc. (SBFM) recorded an outflow of $5.5M in free cash flow during fiscal year 2025. This represents a 61.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sunshine Biopharma Inc.'s operating cash flow?
Sunshine Biopharma Inc. (SBFM) recorded an outflow of $5.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sunshine Biopharma Inc.'s total assets?
Sunshine Biopharma Inc. (SBFM) had $30.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sunshine Biopharma Inc.'s capital expenditures?
Sunshine Biopharma Inc. (SBFM) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sunshine Biopharma Inc. spend on research and development?
Sunshine Biopharma Inc. (SBFM) invested $604K in research and development during fiscal year 2025.
What is Sunshine Biopharma Inc.'s current ratio?
Sunshine Biopharma Inc. (SBFM) had a current ratio of 4.17 as of fiscal year 2025, which is generally considered healthy.
What is Sunshine Biopharma Inc.'s debt-to-equity ratio?
Sunshine Biopharma Inc. (SBFM) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sunshine Biopharma Inc.'s return on assets (ROA)?
Sunshine Biopharma Inc. (SBFM) had a return on assets of -19.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sunshine Biopharma Inc.'s P/E ratio?
Sunshine Biopharma Inc. (SBFM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.7M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Sunshine Biopharma Inc.'s price-to-sales ratio?
Sunshine Biopharma Inc. (SBFM) trades at 0.1x sales, its market capitalization divided by revenue of $35.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.7M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Sunshine Biopharma Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Sunshine Biopharma Inc. (SBFM) held $9.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.3M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Sunshine Biopharma Inc.'s Altman Z-Score?
Sunshine Biopharma Inc. (SBFM) has an Altman Z-Score of -1.92, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sunshine Biopharma Inc.'s Piotroski F-Score?
Sunshine Biopharma Inc. (SBFM) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sunshine Biopharma Inc.'s earnings high quality?
Sunshine Biopharma Inc. (SBFM) reported a net loss of $6.0M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sunshine Biopharma Inc.?
Sunshine Biopharma Inc. (SBFM) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.